| First Author | Mayer-Sonnenfeld T | Year | 2005 |
| Journal | Neurobiol Dis | Volume | 20 |
| Issue | 3 | Pages | 738-43 |
| PubMed ID | 15951190 | Mgi Jnum | J:104630 |
| Mgi Id | MGI:3612555 | Doi | 10.1016/j.nbd.2005.05.009 |
| Citation | Mayer-Sonnenfeld T, et al. (2005) The metabolism of glycosaminoglycans is impaired in prion diseases. Neurobiol Dis 20(3):738-43 |
| abstractText | It is well established that the conversion of PrP(C) to PrP(Sc) is the key event in prion disease biology. In addition, several lines of evidence suggest that glycosaminoglycans (GAGs) and in particular heparan sulfate (HS) may play a role in the PrP(C) to PrP(Sc) conversion process. It has been proposed that PrP(Sc) accumulation in prion diseases may induce aberrant activation of lysosomal activity, which has been shown to result in neurodegeneration in a number of diseases, especially lysosomal storage disorders. Among such diseases, only the ones resulting from defects in GAGs degradation are accompanied by secretion of large amounts of GAG metabolites in urine. In this work, we show that GAGs are secreted in the urine of prion-infected animals and humans, and surprisingly, also in the urine of mice ablated for the PrP gene. We hypothesize that both the presence of PrP(Sc) or the absence of PrP(C) may alter the metabolism of GAGs. |
